United Therapeutics Corporation (UTHR)
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
United Therapeutics Corporation is a Healthcare company with a market capitalization of $23.03B and a trailing P/E ratio of 20.1.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 6, 2026 | $5.82 | $6.86 | -15.2% |
| Q4 2025 | February 25, 2026 | $7.70 | $7.10 | +8.5% |
| Q3 2025 | October 29, 2025 | $7.16 | $6.96 | +2.9% |
| Q2 2025 | July 30, 2025 | $6.41 | $6.94 | -7.6% |
| Q1 2025 | April 30, 2025 | $6.63 | $6.54 | +1.4% |
| Q4 2024 | February 26, 2025 | $6.19 | $6.27 | -1.2% |
Other Drug Manufacturers - Specialty & Generic Stocks
Frequently Asked Questions
What is United Therapeutics Corporation's market cap?
As of June 29, 2026, United Therapeutics Corporation (UTHR) has a market capitalization of $23.03B.
What is United Therapeutics Corporation's P/E ratio?
United Therapeutics Corporation trades at a trailing price-to-earnings (P/E) ratio of 20.1. Its forward P/E is 19.8.
Does United Therapeutics Corporation pay a dividend?
United Therapeutics Corporation does not currently pay a dividend.
What sector is UTHR in?
United Therapeutics Corporation is in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry.
What was United Therapeutics Corporation's revenue?
In its latest reported fiscal year (ending December 31, 2025), United Therapeutics Corporation reported revenue of $3.18B and net income of $1.33B.
Ask your own questions about UTHR
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.